|
| | Test | To evaluate for |
|
| Blood and urine | (A) Complete blood count; blood urea nitrogen, electrolytes, calcium phosphorous, and albumin | (A) Renal function |
| (B) Plasma Renin | (B) Renovascular HT |
| (C) Complements 3 and 4; ANA, antinuclear antibody; anti-DNA and antidouble-stranded desoxynucleic acid antibody | (C) Glomerulonephritis |
| (D) Antineutrophil cytoplasmic antibody (ANCA); anti-GBM and antiglomerular basement membrane antibody | (D) Vasculitis |
| (E) Thyroxine, T4; thyroid stimulating hormone, TSH; adrenocorticotrophic hormone, ACTH; OH, hydroxy; deoxycorticosterone, DOC; parathyroid hormone, PTH | (E) Hormonal |
| (F) Serum and urinary catecholamine and metanephrines | (F) Neurogenic tumors |
|
| Imaging | (A) Renal ultrasound | (A) Renal malformation, medical renal disease, and renal scars |
| (B) Mercaptoacetyltriglycine and MAG 3 scan with or without furosemide. With or without Captopril | (B) Obstuctive uropathy, renovascular HT, and differential renal function |
| (C) Dimercaptosuccinic acid, DMSA | (C) Vesicoureteral reflux and reflux nephropathy; differential renal function |
| (D) Voiding cystourethrogram, VCUG; digital subtraction angiography, DSA | (D) Vesicouretheral reflux and structural bladder abnormalities |
| (E) Magnetic resonance angiography, MRA; digital subtraction angiography, DSA; computed tomographic angiography, CTA; magnetic resonance angiography, MRA | (E) Renovascular |
| (F) MIBG, metaiodobenzylguanidine | (F) Pheochromocytoma |
|
| Tests of end organ damage | (A) Echocardiogram, CXR ECG | (A) Cardiovascular morbidity |
| (B) Urinalysis | (B) Proteinuria |
| (C) Microalbuminuria | (C) Glomerular hyperfiltration |
| (D) Ambulatory BP monitoring | (D) Absence of diurnal rhythm and white coat effect |
|
